Advances in cell and gene therapy are moving at pace. But one of the biggest challenges is ensuring the downstream process produces a safe product consistently, every time.

​

A standard assay like ELISA does not allow for real risk assessment as it cannot identify and quantify all the individual protein impurities in the drug substance.

But the audience is comfortable with ELISA.

It may not give them the full picture, but they’ve learnt to live with its weaknesses because it’s so widely used and accepted by the Regulator. 

​

Alphalyse can help overcome the issues associated with ELISA. Their mass spectrometry services help optimize the CMC process and monitor product and process-related proteins. However, the audience didn’t realise this technology is now easily accessible thanks to Alphalyse.

Our marketing campaign 'Are you thinking what others are thinking?" tapped into insight from audience research. We needed to create our ‘stop and think’ moments that would make them consider changing their usage behaviour.

 

To become the first choice, first Alphyse's offering had to become a choice.